Sara Collins, MD
Cardiovascular Disease · Bowie, MDNPI 1023275229
Payments from drug & device makers
Across 267 payments — averaging $1689.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cleerly, Inc.$251K
- Amgen$112K
- Novartis$29K
- Genentech, Inc.$24K
- Eli Lilly$8K
- UCB, Inc.$8K
- plus $20K from 31 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Cleerly, Inc. | 31 | $250,737 |
| Amgen | 33 | $111,790 |
| Novartis | 29 | $29,014 |
| Genentech, Inc. | 8 | $23,846 |
| Eli Lilly | 21 | $7,855 |
| UCB, Inc. | 8 | $7,595 |
| Pfizer | 15 | $6,347 |
| Bayer | 7 | $5,120 |
| Novo Nordisk | 13 | $3,820 |
| Abbott | 21 | $1,577 |
| Merck | 12 | $1,032 |
| Alnylam Pharmaceuticals Inc. | 8 | $362 |
| AstraZeneca | 11 | $228 |
| Medtronic | 3 | $210 |
| Boston Scientific | 4 | $173 |
| Johnson & Johnson | 7 | $136 |
| Cardiovascular Systems Inc. | 1 | $129 |
| Edwards Lifesciences | 1 | $119 |
| Regeneron Healthcare Solutions, Inc. | 5 | $118 |
| Biotronik Inc. | 1 | $110 |
| E.r. Squibb & Sons, L.L.C. | 5 | $106 |
| Astellas Pharma Global Development | 1 | $91 |
| Esperion Therapeutics, Inc. | 3 | $71 |
| Gilead | 3 | $52 |
| Philips North America LLC | 2 | $48 |
| Heartflow, Inc. | 2 | $45 |
| Amarin Pharma, Inc. | 2 | $38 |
| Actelion Pharmaceuticals US, Inc. | 1 | $35 |
| Boehringer Ingelheim | 1 | $33 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $33 |
| Atricure, Inc. | 1 | $28 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $27 |
| Sanofi-aventis U.S. LLC | 1 | $22 |
| Arbor Pharmaceuticals, Inc. | 1 | $17 |
| Impulse Dynamics (USA) Inc. | 1 | $17 |
| Irhythm Technologies, Inc. | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
How this compares
$451,011 in reported general payments places this provider in the 95th percentile of 507 cardiovascular disease providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other cardiovascular disease in Bowie
- Barbara HutchinsonBowie$803K
- Christopher DefilippiBaltimore$9.2M
- Thorsten LeuckerBaltimore$7.1M
- Joao LimaBaltimore$5.6M
- Jeffrey ColeBaltimore$4.8M
- Carlos InceBaltimore$3M
- Paul GurbelBaltimore$2.6M
- Navin KapurBaltimore$1.8M
- Vineet VenugopalLanham$1.5M
- Robert WeissBaltimore$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.